Cyclic RGD peptide-modified liposomal drug delivery system: Enhanced cellular uptake in vitro and improved pharmacokinetics in rats

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3803-3811

  Chen, Zhongya ^a,b   Deng, Jiaxin ^a,b   Zhao, Yan ^a,b   Tao, Tao ^a,b  

^a National Pharmaceutical Engineering Research Center   (China)

^b Shanghai Institute of Pharmaceutical Industry   (China)

Author keywords

Covalent coupling; Doxorubicin; Drug targeting; Human glioma; Post insertion; Sterically stabilized liposomes

Indexed keywords

CYCLIC ARGININE GLYCINE ASPARTATE DEXTRO PHENYLALANINE CYSTINE LIPOSOME; DOXORUBICIN; LIPOSOME; MACROGOL 2000; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL TRANSPORT; CIRCULATION TIME; CONTROLLED STUDY; DRUG CLEARANCE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG STABILITY; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MALE; MEAN RESIDENCE TIME; NANOENCAPSULATION; NONHUMAN; PROTEIN MOTIF; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FLOW CYTOMETRY; GLIOMA; HUMANS; LIPOSOMES; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84870361888     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33541     Document Type: Article

References (44)

1. Banerjee R. Liposomes: applications in medicine. J Biomater Appl. 2001;16(1):3-21.
2. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003;6(5):271-279.
3. Moghimi S, Patel H. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-the concept of tissue specificity. Adv Drug Deliv Rev. 1998;32(1-2):45-60.
4. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297-315.
5. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54(13):3352-3356.
6. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41(1):189-207.
7. Suzuki S, Watanabe S, Masuko T, Hashimoto Y. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol). Biochim Biophys Acta. 1995;1245(1):9-16.
8. Moreira JN, Gaspar R, Allen TM. Targeting stealth liposomes in a murine model of human small cell lung cancer. Biochim Biophys Acta. 2001;1515(2):167-176.
9. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56(8):1177-1192.
10. Derycke ASL, Kamuhabwa A, Gijsens A, etal. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J Natl Cancer Inst. 2004;96(21):1620-1630.
11. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release. 2004;100(1):135-144.
12. Hamaguchi T, Matsumura Y, Nakanishi Y, etal. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 2004;95(7):608-613.
13. Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K, Nagaike K. Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br J Cancer. 2003;89(8):1545-1551.
14. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly (ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta. 1995;1234(1):74-80.
15. Matsumura Y, Gotoh M, Muro K, etal. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004;15(3):517-525.
16. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin α2β1. Cell. 2000;101(1):47-56.
17. Xiong JP, Stehle T, Zhang R, etal. Crystal structure of the extracellular segment of integrin alpha Vbeta 3in complex with an Arg-Gly-Asp ligand. Science. 2002;296(5565):151-155.
18. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci. 2006;119(19):3901-3903.
19. Shimaoka M, Xiao T, Liu JH, etal. Structures of the αL I domain and its complex with ICAM-1reveal a shape-shifting pathway for integrin regulation. Cell. 2003;112(1):99-111.
20. Keenan RM, Callahan JF, Samanen JM, etal. Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists. J Med Chem. 1999;42(4):545-559.
21. Fisher MJ, Gunn B, Harms CS, etal. Non-peptide RGD surrogates which mimic a Gly-Asp β-turn: potent antagonists of platelet glycoprotein IIb-IIIa. J Med Chem. 1997;40(13):2085-2101.
22. Zablocki JA, Miyano M, Garland RB, etal. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor. J Med Chem. 1993;36(13):1811-1819.
23. Egbertson MS, Chang CTC, Duggan ME, etal. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem. 1994;37(16):2537-2551.
24. Zablocki JA, Rico JG, Garland RB, etal. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (aminobenzamidino) succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J Med Chem. 1995;38(13):2378-2394.
25. Hutchinson JH, Cook JJ, Brashear KM, etal. Non-peptide glycoprotein IIb/IIIa antagonists. II. Design and in vivo evaluation of 3, 4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs. J Med Chem. 1996;39(23):4583-4591.
26. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12(1):697-715.
27. Kim CK, Lim SJ. Liposome immunoassay (LIA) with antigen-coupled liposomes containing alkaline phosphatase. J Immunol Methods. 1993;159(1-2):101-106.
28. Kim CK, Choi YJ, Soo-Jeong L, Lee MG, Lee SH, Hwang SJ. Lymph node targeting and pharmacokinetics of [3H] methotrexate-encapsulated neutral large unilamellar vesicles and immunoliposomes. Int J Pharm. 1993;98(1-3):9-18.
29. Rink H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin. Tetrahedron Lett. 1987;28(33):3787-3790.
30. Barany G, Kneib-Cordonier N, Mullen DG. Solid-phase peptide synthesis: a silver anniversary report. Int J Pept Protein Res. 1987;30(6):705-739.
31. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151(2):201-215.
32. Bolotin EM, Cohen R, Bar LK, etal. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res. 1994;4(1):455-479.
33. Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ. Insertion of poly (ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett. 1996;386(2-3):243-246.
34. Nallamothu R, Wood GC, Pattillo CB, etal. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation. AAPS Pharm Sci Tech. 2006;7(2):7-16.
35. Shinozawa S, Mimaki Y, Araki Y, Oda T. Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography. J Chromatogr. 1980;196(3):463-469.
36. Vaage J, Mayhew E, Lasic D, Martin F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer. 1992;51(6):942-948.
37. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001;1(6):923-947.
38. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta. 1995;1239(2):133-144.
39. Moreira JN, Ishida T, Gaspar R, Allen TM. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res. 2002;19(3):265-269.
40. Xiong XB, Huang Y, Lu W, etal. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 2005;107(2):262-275.
41. Xiang G, Wu J, Lu Y, Liu Z, Lee RJ. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int J Pharm. 2008;356(1):29-36.
42. Iinuma H, Maruyama K, Okinaga K, etal. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 2002;99(1):130-137.
43. Turk MJ, Waters DJ, Low PS. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 2004;213(2):165-172.
44. Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Pharm Res. 1996;13(6):861-868.